NCT05641831 2026-01-02
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
1 trialsClonal Cytopenia of Undetermined Significance × Specimen Handling × Classical hematology × Clear all